- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00045318
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction
A Phase I Study of DX-8951f (Exatecan Mesylate for Injection) in Patients With Renal Dysfunction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients who have advanced solid tumors and kidney dysfunction.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the maximum tolerated dose of exatecan mesylate in patients with advanced solid tumors and varying degrees of renal dysfunction.
- Determine the dose-limiting and non-dose-limiting toxic effects of this drug in these patients.
- Determine the effects of renal dysfunction on the plasma pharmacokinetics and pharmacodynamics of this drug in these patients.
- Establish a model for dosing this drug in patients with impaired renal function.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to severity of renal dysfunction (normal vs mild vs moderate vs severe).
Patients receive exatecan mesylate IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients in each renal dysfunction stratum receive escalating doses of exatecan mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients in the normal renal function stratum do not undergo dose escalation.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 45 patients (6 normal, 9 mild, 12 moderate, and 18 severe renal dysfunction) will be accrued for this study within 1.5 years.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Texas
-
Fort Sam Houston, Texas, United States, 78234
- Brooke Army Medical Center
-
San Antonio, Texas, United States, 78284
- Veterans Affairs Medical Center - San Antonio (Murphy)
-
San Antonio, Texas, United States, 78229
- Cancer Therapy and Research Center
-
San Antonio, Texas, United States, 78229
- St. Luke's Lutheran Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed advanced solid tumor refractory to standard therapy or for which no standard therapy exists
Renal function as defined by the following parameters:
- Normal (creatinine clearance (CrCl) greater than 80 mL/min)
- Mild dysfunction (CrCl 50-80 mL/min)
- Moderate dysfunction (CrCl 30-50 mL/min)
- Severe dysfunction (CrCl less than 30 mL/min)
- End-stage renal disease (requiring dialysis)
- No symptomatic or active brain metastases (e.g., edema or progression on CT scan or MRI)
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- At least 12 weeks
Hematopoietic
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 9.0 g/dL
Hepatic
- Bilirubin normal
- AST or ALT no greater than 2 times upper limit of normal
- Albumin at least 2.8 g/dL
Renal
- See Disease Characteristics
Cardiovascular
- No active congestive heart failure
- No uncontrolled angina
- No myocardial infarction within the past 6 months
Other
- No concurrent serious infection
- No other life-threatening illness
- No overt psychosis or mental disability or other incompetency that would preclude informed consent
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent anticancer biologic therapy
Chemotherapy
- At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea) and recovered
- No prior exatecan mesylate
- No other concurrent anticancer chemotherapy
Endocrine therapy
- No concurrent anticancer hormonal therapy
- Concurrent megestrol for appetite stimulation allowed
Radiotherapy
- At least 4 weeks since prior radiotherapy and recovered
- No concurrent anticancer radiotherapy
Surgery
- At least 4 weeks since prior major surgery and recovered
- No concurrent anticancer surgery
Other
- At least 4 weeks since prior investigational drugs including analgesics or antiemetics
- At least 1 week since prior grapefruit juice
- No other concurrent anticancer therapy
- No other investigational drugs during and for 4 weeks after study
- No concurrent grapefruit juice
- No other concurrent anticancer cytotoxic therapy
- Concurrent chronic hemodialysis or ambulatory peritoneal dialysis allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Carolyn Britten, MD, Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAIICHI-8951A-PRT026
- UCLA-0201008
- CDR0000256866 (Registry Identifier: PDQ (Physician Data Query))
- NCI-G02-2103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on exatecan mesylate
-
European Organisation for Research and Treatment...CompletedSarcomaBelgium, Germany, Slovakia, Denmark
-
Daiichi Sankyo, Inc.CompletedSarcomaUnited States, Canada
-
Daiichi Sankyo, Inc.CompletedGastric Cancer | Esophageal CancerUnited States, Canada
-
Daiichi Sankyo, Inc.CompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
Daiichi Sankyo, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States
-
Daiichi Sankyo, Inc.Completed
-
Daiichi PharmaceuticalsCompletedLung CancerGermany, United Kingdom, Finland, Italy, Netherlands
-
Daiichi Sankyo, Inc.CompletedPancreatic CancerUnited States
-
Daiichi Sankyo, Inc.Completed
-
Daiichi Sankyo, Inc.Completed